Algorae Pharmaceuticals (ASX:1AI) Tax Expense: A$-1.12 Mil (TTM As of Dec. 2025)


What is Algorae Pharmaceuticals Tax Expense?

Algorae Pharmaceuticals ASX:1AI Tax Expense is A$-1.12 Mil as of Dec. 2025. The stock has 2 warning signs investors should review.

Algorae Pharmaceuticals's tax expense for the months ended in Dec. 2025 was A$-0.38 Mil. Its tax expense for the trailing twelve months (TTM) ended in Dec. 2025 was A$-1.12 Mil.


Algorae Pharmaceuticals  (ASX:1AI) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


Algorae Pharmaceuticals Tax Expense Related Terms


Algorae Pharmaceuticals Tax Expense Historical Data

* Premium members only.

The historical data trend for Algorae Pharmaceuticals's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Algorae Pharmaceuticals Tax Expense Chart

Algorae Pharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Tax Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.45 -0.42 0.00 0.00 -0.74

Algorae Pharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Tax Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -0.74 -0.38

Algorae Pharmaceuticals Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-1.12 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Expense →
What does a Tax Expense of A$-1.12 Mil mean?
Algorae Pharmaceuticals (ASX:1AI) has a Tax Expense of A$-1.12 Mil as of Dec. 2025. Tax expense is the amount of tax the company pays in an accounting period. View historical data on Algorae Pharmaceuticals and its competitors.
Is Algorae Pharmaceuticals' Tax Expense too high?
Algorae Pharmaceuticals' current Tax Expense is A$-1.12 Mil.
How does Algorae Pharmaceuticals' Tax Expense compare to VRTX and REGN?
Algorae Pharmaceuticals' Tax Expense of A$-1.12 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Expense for a Biotechnology company?
A good Tax Expense depends on the Biotechnology industry context. However, Tax Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Expense mean?
A high Tax Expense can signal that a stock is expensive relative to its fundamentals. Tax expense is the amount of tax the company pays in an accounting period. View historical data on Algorae Pharmaceuticals and its competitors. Algorae Pharmaceuticals's current Tax Expense is A$-1.12 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Algorae Pharmaceuticals stock overvalued right now?
Algorae Pharmaceuticals (ASX:1AI) has a current Tax Expense of A$-1.12 Mil. The current Tax Expense is A$-1.12 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Expense calculated?
Tax Expense is calculated from a company's financial statements. For Algorae Pharmaceuticals (ASX:1AI), the current Tax Expense is A$-1.12 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Algorae Pharmaceuticals Business Description

Other Exchanges LVCLF:USALHI0:Germany
Address 525 Collins Street, Level 23, Rialto South Tower, Melbourne, VIC, AUS, 3000
Algorae Pharmaceuticals Ltd is a clinical-stage pharmaceutical company developing transformative solutions for under met medical needs in the community. The firm develops AlgoraeOS, a closed-loop platform, leveraging computational tools to generate novel insights in silico that are being developed to initiate or accelerate therapeutic programs. The products of the company comprise AI-116, a novel combination drug candidate of cannabidiol (CBD) and an off-patent pharmaceutical ingredient. The company is conceptualized to be a potential treatment for dementia, including Alzheimer's disease, NTCELL is an alginate-coated capsule containing clusters of neonatal porcine choroid plexus cells. It also offers LP-003 Anti-obesity Drug and LC-002 migraine treatment.